Changes in Hong Kong stocks | Xianjian Technology (01302) rose more than 3%, SureCham™ single-branch stents entered the special review process for innovative medical devices

The Zhitong Finance App learned that Xianjian Technology (01302) rose more than 3%. As of press release, it had risen 3.07% to HK$1,345, with a turnover of HK$5.5836 million.

According to the news, Xianjian Technology issued an announcement. On September 24, 2026, the company received an official written notice from the State Drug Administration confirming that the SureCham™ aortic arch single-branch laminating stent system (sureCham™ single-branch stent or “this product”), which was jointly developed by the company and Professor Shu Chang's team from Fuwai Hospital of the Chinese Academy of Medical Sciences of the National Cardiovascular Center, has entered the China Drug Administration's special review procedure (this procedure). This product is suitable for treating aortic dissection involving the active arch. It is the company's 19th product to enter this procedure by the State Drug Administration.

The Group owns independent intellectual property rights for this product. Currently, SureCham™ single-branch stents have been used clinically in some countries and regions in Europe and Asia, and their excellent performance and clinical value have been highly recognized and paid widespread attention by international clinical experts. The product will combine the aortic arch branch reconstruction chimney technology innovation product matrix, the aortic arch branch reconstruction in-situ window opening technology innovation product matrix, and the CS™ integrated arch branch reconstruction system to form the company's unique overall solution for intracavitary treatment of aortic arch lesions.